Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John G Doench

Showing results (171-180 of 186) with videos related to

Pageof 19
Sort By:
Nature Cancer|April 19, 2022
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancerDaniel P Bondeson, Brenton R Paolella, Adhana Asfaw, et al.
Cancer Discovery|September 2, 2025
Defining the antitumor mechanism of action of a clinical-stage compound as a selective degrader of the nuclear pore complexLinjie Yuan, Wenzhi Ji, Brendan G Dwyer, et al.
Nature|May 6, 2021
Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicityGabriel K Griffin, Jingyi Wu, Arvin Iracheta-Vellve, et al.
Cell|November 4, 2020
Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 InfectionJin Wei, Mia Madel Alfajaro, Peter C DeWeirdt, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosisJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.
Nature Immunology|September 23, 2022
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancerJuan Dubrot, Peter P Du, Sarah Kate Lane-Reticker, et al.
Nature Communications|July 24, 2025
HKU5 bat merbecoviruses engage bat and mink ACE2 as entry receptorsMia Madel Alfajaro, Emma L Keeler, Ning Li, et al.
Nature Cancer|July 3, 2020
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profilingSteven M Corsello, Rohith T Nagari, Ryan D Spangler, et al.
Science (New York, N.Y.)|April 9, 2026
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunityJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.
Nature|July 6, 2017
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathwayVasanthi S Viswanathan, Matthew J Ryan, Harshil D Dhruv, et al.
Pageof 19

Showing results (171-180 of 186) with videos related to

Sort By:
Pageof 19
Nature Cancer|April 19, 2022
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancerDaniel P Bondeson, Brenton R Paolella, Adhana Asfaw, et al.
Cancer Discovery|September 2, 2025
Defining the antitumor mechanism of action of a clinical-stage compound as a selective degrader of the nuclear pore complexLinjie Yuan, Wenzhi Ji, Brendan G Dwyer, et al.
Nature|May 6, 2021
Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicityGabriel K Griffin, Jingyi Wu, Arvin Iracheta-Vellve, et al.
Cell|November 4, 2020
Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 InfectionJin Wei, Mia Madel Alfajaro, Peter C DeWeirdt, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosisJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.
Nature Immunology|September 23, 2022
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancerJuan Dubrot, Peter P Du, Sarah Kate Lane-Reticker, et al.
Nature Communications|July 24, 2025
HKU5 bat merbecoviruses engage bat and mink ACE2 as entry receptorsMia Madel Alfajaro, Emma L Keeler, Ning Li, et al.
Nature Cancer|July 3, 2020
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profilingSteven M Corsello, Rohith T Nagari, Ryan D Spangler, et al.
Science (New York, N.Y.)|April 9, 2026
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunityJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.
Nature|July 6, 2017
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathwayVasanthi S Viswanathan, Matthew J Ryan, Harshil D Dhruv, et al.
Pageof 19